Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Baxter, Kuros Biosurgery in tissue repair deal; then Kuros regains rights to most candidates

Executive Summary

Baxter's biosurgery business is entering the orthobiologics market. It has licensed exclusive worldwide rights to develop and market a portfolio of bone and soft tissue repair products that will use the company's Tisseel fibrin biomatrix in combination with biologic agents and related binding technology that were invented by Kuros Biosurgery AG.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
  • Medical Devices
    • Biomaterials
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies